promotional of c-pulse, page-25

Piper Jaffray & Co. senior analyst Thomas Gunderson said the product has a potential worldwide market of up $1 billion.

“All of that makes it intriguing and interesting to the investment clientele,” ­Gunderson said. “Not only is it a bigger market, but the technology seems to have grabbed the attention of big-name ­physicians.”

"Gunderson said the impact of reducing hospitalizations or even healing the heart could be significant on the firm’s fortunes."

http://www.startribune.com/business/230297291.html

lets hear them big name physicians and clients who have come off the C-pulse device.

It appears to me a lot of money has been invested in HTWR and THOR by insto's who own a lot of stock , insto's own 93% of HTWR and 90% of THOR or around $3.3B combined . Will the success of C-pulse remove a large portion of the class 4 market and make HTWR AND THOR stocks fall. A SSH rally would question the value of HTWR and THOR .What portion of the class 4 market come from class 3 now. I would assume all of them.

Regarding Angina which is heart pain , surely a lot of class 3 patients have it , why isnt it one of the outcomes the trial will look for. Is that something that has to have its own trial.